Oramed Pharmaceuticals CFO Avraham Gabay sells $90,200 in stock

Oramed Pharmaceuticals CFO Avraham Gabay sold 20,000 shares of the company's stock on October 1, 2026, for a total of $90,200. The transaction was carried out under a Rule 10b5-1 trading plan adopted by Mr. Gabay on March 30, 2026. Prior to the sale, Mr. Gabay owned 861,076 shares of Oramed Pharmaceuticals common stock. The sale occurred as the company's shares have seen significant growth, increasing by 92% over the past year and 31% in the last six months.

Oramed Pharmaceuticals trades at $4.49 per share with a market capitalization of $184.69 million. Analysts consider the stock to be undervalued at its current price, offering a dividend yield of 5.58%. Investors can find additional insights from 10 InvestingPro Tips, which provide further analysis of the company's financial metrics and fair value.

Recently, Oramed Pharmaceuticals Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved six proposals. The company's current directors, Dr. Daniel Aghion, Dr. Miriam Kidron, Nadav Kidron, Dr. Arie Mayer, Yehuda Reznick, and Benjamin Shapiro, received re-elections for their terms, which will continue until the next annual meeting or until successors are elected.

Shareholder approval ranged from 11,567,510 to 13,702,335 votes in favor, while between 3,729,485 and 5,859,953 votes were against. This reaffirms the continued backing from shareholders for the company's leadership and strategic direction.